Bedu-Addo Frank reported grant involving 16,556,733 derivative units of PDS Biotechnology Corp at $0.00 for $0 on Nov 16, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
President/CEO
President/CEO
Filed Nov 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
16,556,733Employee Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
16,556,733Direct
Trade date
Nov 16, 2026Grant
Filed
Nov 17, 2026, 4:42 PM ET1-day reporting delay
Accession
0001140361-26-044530Code A · Transaction 403821
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 16, 2026Grant2,698,978$0.00$0Trade 403820
2 transaction rows in this filing. Joint filers share the same rows.

PDSB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PDSB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago +21%1d ago −2.2%
Returns since7d30d90d180d1y

Footnotes in full

F1: The option is fully vested and exercisable. F2: The option was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained. Contingent upon stockholder approval, the shares subject to the option shall vest in equal monthly installments over four (4) years, beginning on December 16, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation.